Inhaled drug developer Senzer has announced major changes to its management “aimed at bolstering its commercialization strategy for COVID-19 and cannabinoid treatments.” In May 2020, Senzer announced that it was developing two inhaled anti-virals delivered via MDI for the treatment of COVID-19 in addition to the cannabinoids it is developing based on its Systemic Inhaled Delivery Device.
The company named Barbara Staehelin as Chairman of its board and added Izana Bioscience Chief Medical Officer Tim Corn and former Smith & Nephew CMO Andy Weymann as non-executive directors. Staehlin co-founded healthcare software company Axicos and served as its Chairman, beginning in 2007.
Senzer also named its former Chairman Adam Kelliher as the new CEO, succeeding Alex Hearn, who will remain as Deputy Chairman. In addition, the company promoted Matt McKevitt to Chief Operating Officer; appointed former GW Pharmaceuticals International Medical Director Andrew Saich as CMO; and named former BMS Legal and Compliance Director Wendy Lloyd-Goodwin as General Counsel.
Kelliher commented, “We now have in place a highly experienced executive team and a very focused board. These appointments are crucial as our unique respiratory offerings will soon be ready for patients and users. We all owe so much to Alex Hearn, under whose leadership Senzer has developed a remarkable product pipeline that enables us to now take the company into a commercial execution phase.”
Read the Senzer press release.
